Thank you for sharing!

Your article was successfully shared with the contacts you provided.
DaVita Inc.’s $3.05 billion acquisition of Gambro Healthcare US is expected to encounter antitrust trouble in the U.S., though it appears the companies should be able to secure clearance to close the deal. “This is a merger that will get considerable attention,” said David Balto, a partner at Robins, Kaplan, Miller & Ciresi in Washington. The government, through the Medicare program, pays the treatment costs for many dialysis patients. Given the size of the expense, antitrust enforcers will be especially thorough in their review, Balto said. The merger, formally unveiled Tuesday would make DaVita the biggest dialysis provider in the U.S., with about 1,200 clinics. German giant Fresenius Medical Care AG has 1,110 U.S. clinics. Third is Renal Care Group Inc., with roughly 370. Antitrust experts said the Department of Justice, which is expected to conduct the review, must first determine if there is a national market for dialysis treatment. Such a market could exist if enough insurers testify that they pit DaVita against Gambro to get price cuts. “If enough insurers need national providers, then there could be a national market,” Balto said. Assuming there is not a national market, enforcers will look at very narrow geographic markets because patients who need dialysis cannot travel far for an alternative clinic. That suggests the investigation could take several months at minimum to complete. Enforcers will need to check not just which of the national chains have clinics near the Gambro facilities, but also must identify the many hospitals and smaller organizations that offer dialysis treatment. Until such a review is complete, it is impossible to know whether DaVita will have to divest many clinics to satisfy the Justice Department. But experts said at least some divestitures are likely, given the size of the two operations. Copyright �2004 TDD, LLC. All rights reserved.

This content has been archived. It is available exclusively through our partner LexisNexis®.

To view this content, please continue to Lexis Advance®.

Not a Lexis Advance® Subscriber? Subscribe Now

Why am I seeing this?

LexisNexis® is now the exclusive third party online distributor of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® customers will be able to access and use ALM's content by subscribing to the LexisNexis® services via Lexis Advance®. This includes content from the National Law Journal®, The American Lawyer®, Law Technology News®, The New York Law Journal® and Corporate Counsel®, as well as ALM's other newspapers, directories, legal treatises, published and unpublished court opinions, and other sources of legal information.

ALM's content plays a significant role in your work and research, and now through this alliance LexisNexis® will bring you access to an even more comprehensive collection of legal content.

For questions call 1-877-256-2472 or contact us at [email protected]


ALM Legal Publication Newsletters

Sign Up Today and Never Miss Another Story.

As part of your digital membership, you can sign up for an unlimited number of a wide range of complimentary newsletters. Visit your My Account page to make your selections. Get the timely legal news and critical analysis you cannot afford to miss. Tailored just for you. In your inbox. Every day.

Copyright © 2020 ALM Media Properties, LLC. All Rights Reserved.